As the cost of capital increases, Silicon Valley venture capitalists will be busy amidst a period of consolidation and transformation of healthcare startups. Venture capital firms will dictate investor-friendly terms to companies that find themselves in the unfortunate position of raising capital in this environment to launch new drugs.